Dynavax Technologies
DVAX
Market cap $1.23B

10.27 USD

-0.13

1.25%

At close Jun 13, 4:00 PM EDT

After hours

10.21

-0.06

0.58%

1 day

-1.25%

5 days

0.39%

1 month

6.76%

3 months

-24.98%

6 months

-20.76%

Year to date

-20.39%

1 year

-14.49%

5 years

59.97%

10 years

-50.17%

About: Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

Employees: 405

Healthcare Drug Manufacturers - Specialty & Generic

0

Funds holding %

of 7,296 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

159% more first-time investments, than exits

New positions opened: 44 | Existing positions closed: 17

121% more call options, than puts

Call options by funds: $7.3M | Put options by funds: $3.3M

9% more funds holding

Funds holding: 255 [Q4 2024] → 279 (+24) [Q1 2025]

3.36% more ownership

Funds ownership: 99.3% [Q4 2024] → 102.66% (+3.36%) [Q1 2025]

1% less capital invested

Capital invested by funds: $1.67B [Q4 2024] → $1.65B (-$14.8M) [Q1 2025]

5% less repeat investments, than reductions

Existing positions increased: 92 | Existing positions reduced: 97

20% less funds holding in top 10

Funds holding in top 10: 5 [Q4 2024] → 4 (-1) [Q1 2025]

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$10

3%

downside

Avg. target

$21

100%

upside

High target

$31

202%

upside

2 analyst ratings

1 positive

50%

0 neutral

0%

1 negative

50%

JMP Securities Roy Buchanan	202%upside $31	Market Outperform Maintained	7 May 2025
Goldman Sachs Paul Choi	3%downside $10	Sell Maintained	17 Apr 2025

See Analyst Rankings

Financial journalist opinion

Based on 11 articles about DVAX published over the past 30 days

Dynavax elects all four of its nominees after Deep Track proxy fight

Biopharmaceutical company Dynavax Technologies on Wednesday defeated investment firm Deep Track Capital's effort to unseat directors when investors re-elected all four candidates, the company said.

Dynavax elects all four of its nominees after Deep Track proxy fight

Dynavax Stockholders Elect All Dynavax Director Nominees at 2025 Annual Meeting

EMERYVILLE, Calif. , June 11, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that, based on the preliminary vote count provided by its proxy solicitor following the Company's 2025 Annual Meeting of Stockholders ("Annual Meeting"), Dynavax stockholders have voted to elect all four of its director nominees – Brent MacGregor, Scott Myers, Lauren Silvernail and Elaine Sun – to the Company's Board of Directors.

Dynavax Stockholders Elect All Dynavax Director Nominees at 2025 Annual Meeting

Deep Track Capital Sends Letter to Dynavax Technologies Shareholders Offering Final Perspectives on Why Change is Needed in the Boardroom

GREENWICH, Conn.--(BUSINESS WIRE)--Deep Track Capital, LP, (together with its affiliates, “Deep Track” or “we”), one of the largest shareholders of Dynavax Technologies Corporation (NASDAQ: DVAX) (“Dynavax”, “DVAX” or the “Company”), with ownership of approximately 14.82% of the Company's outstanding shares, today issued a letter to shareholders detailing the benefits of electing Deep Track's four nominees – Brett Erkman, Jeffrey Farrow, Michael Mullette and Donald Santel – to the Board of Dire.

Deep Track Capital Sends Letter to Dynavax Technologies Shareholders Offering Final Perspectives on Why Change is Needed in the Boardroom

Dynavax Urges Stockholders to Support Its Director Nominees at June 11 Annual Meeting

Dynavax's Strategy is Delivering Significant Long-Term Stockholder Value Dynavax's Nominees Are Vastly Superior to Deep Track's Candidates Across Every Critical Area Follow Recommendations of Proxy Advisory Firms ISS and Egan-Jones and Vote "FOR" All Four of Dynavax's Director Nominees on the GOLD Proxy Card Today EMERYVILLE, Calif. , June 9, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today issued the following statement reiterating to stockholders its recommendation to vote "FOR" all four of Dynavax's highly qualified directors standing for election – Brent MacGregor, Scott Myers, Lauren Silvernail and Elaine Sun – at the Company's upcoming Annual Meeting of Stockholders on June 11, 2025 (the "2025 Annual Meeting").

Dynavax Urges Stockholders to Support Its Director Nominees at June 11 Annual Meeting

Dynavax Comments on Glass Lewis Recommendation

Dynavax is Already Delivering Significant Long Term Stockholder Value Through Execution of Current Strategy Overseen by Board; Deep Track's Inferior Short-Term Plan and Nominees are Not in the Best Interests of All Stockholders Glass Lewis' Recommendation Recognizes the Significant Stockholder Value Creation and Differentiated Capital Return Overseen by the Dynavax Board Reiterates ISS and Egan Jones Recommendations that Stockholders Support ALL Dynavax Nominees and Deep Track Board Representation is Not Warranted Urges Stockholders to Vote "FOR" ALL Four of Dynavax's Highly Qualified Director Nominees on the GOLD Proxy Card Today EMERYVILLE, Calif. , June 4, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today commented on a report published by Glass, Lewis & Co. ("Glass Lewis") in connection with the election of the Company's director nominees – Brent MacGregor, Scott Myers, Lauren Silvernail and Elaine Sun – at its Annual Meeting of Stockholders on June 11, 2025 (the "2025 Annual Meeting"): We strongly disagree with Glass Lewis' recommendation against two of our highly qualified directors.

Dynavax Comments on Glass Lewis Recommendation

Glass Lewis Recommends Shareholders Support Deep Track's Case for Board Change at Dynavax Technologies

GREENWICH, Conn.--(BUSINESS WIRE)--Deep Track Capital, LP, (together with its affiliates, “Deep Track” or “we”), one of the largest shareholders of Dynavax Technologies Corporation (NASDAQ: DVAX) (“Dynavax”, “DVAX” or the “Company”), with ownership of approximately 14.82% of the Company's outstanding shares, today announced that leading independent proxy advisory firm Glass, Lewis & Co. (“Glass Lewis”) has recommended shareholders support boardroom change by voting for the election of Deep.

Glass Lewis Recommends Shareholders Support Deep Track's Case for Board Change at Dynavax Technologies

Dynavax to Present at William Blair's 45th Annual Growth Stock Conference

EMERYVILLE, Calif. , May 28, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will present at William Blair's 45th Annual Growth Stock Conference on Tuesday, June 3rd at 2:40 p.m.

Dynavax to Present at William Blair's 45th Annual Growth Stock Conference

Deep Track Capital Comments on ISS Recommendation

GREENWICH, Conn.--(BUSINESS WIRE)--Deep Track Capital, LP, (together with its affiliates, “Deep Track” or “we”), one of the largest shareholders of Dynavax Technologies Corporation (NASDAQ: DVAX) (“Dynavax”, “DVAX” or the “Company”), with ownership of approximately 14.82% of the Company's outstanding shares, today issued the following statement in response to a report issued by Institutional Shareholder Services Inc. (“ISS”) regarding the election of directors to the Company's Board of Director.

Deep Track Capital Comments on ISS Recommendation

ISS backs Dynavax directors in board fight with Deep Track Capital

Proxy advisory firm Institutional Shareholder Services urged Dynavax Technologies shareholders on Friday to reelect all its company directors instead of backing life sciences investment firm Deep Track Capital's four nominees.

ISS backs Dynavax directors in board fight with Deep Track Capital

Leading Independent Proxy Advisory Firm ISS Recommends Stockholders Vote "FOR" All Four of Dynavax's Highly Qualified Director Nominees

ISS Recognizes There is No Case for Change Dynavax's Superior Strategy and Current Board are Best Equipped to Deliver Significant Long-Term Stockholder Value Dynavax Comments on Deep Track's Misleading Supplemental Materials Urges Stockholders to Follow ISS Recommendation and Vote "FOR" ALL Four of Dynavax's Highly Qualified Director Nominees on the GOLD Proxy Card Today EMERYVILLE, Calif. , May 23, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that leading independent proxy advisory firm, Institutional Shareholder Services ("ISS"), has recommended that Dynavax stockholders vote "FOR" all four of the Company's director nominees standing for election – Brent MacGregor, Scott Myers, Lauren Silvernail and Elaine Sun – at the Company's upcoming Annual Meeting of Stockholders on June 11, 2025.

Leading Independent Proxy Advisory Firm ISS Recommends Stockholders Vote "FOR" All Four of Dynavax's Highly Qualified Director Nominees

See News Rankings

Charts implemented using Lightweight Charts™